前列腺支架:功能结局与并发症率的系统评价与分析
该系统评价纳入38篇文章、2618例患者,评估前列腺支架或镍钛器件治疗良性前列腺增生所致下尿路症状的功能结局与并发症。平均年龄72.01±5.6岁,无导尿管率85.2%,并发症率30.83%,12个月随访失败率14.8%,国际前列腺症状评分总体改善9.85分。作者认为前列腺支架仍是有效选择,但需前瞻性研究证实。
要点
- 纳入38篇文章共2618例患者,最常见支架为UroLume,其次为Memokath/Memotherm。
- 无导尿管率85.2%,并发症率30.83%,最常见并发症为尿路感染(17.2%)。
- 12个月随访支架移除或重置的失败率为14.8%,国际前列腺症状评分总体改善9.85分。
核心结论
- 前列腺支架仍是处理良性前列腺增生所致梗阻症状的有效选择,具有局部麻醉下完成、缓解症状且功能结局良好、主要并发症发生率低的优势。
- 作者认为需要前瞻性研究来证实这些结果。
研究设计与样本
- 系统评价,检索截至2023年10月的文献,仅纳入英文原创文章,已在PROSPERO注册(注册号CRD42023474884)。
- 共纳入38篇文章、2618例患者。
- 总体偏倚风险被评为高或非常高。
主要发现
- 最常研究的支架为UroLume,其次为Memokath/Memotherm。
- 平均年龄72.01±5.6岁,平均前列腺体积48.27±12.8 cc,平均尿道长度40.53±9.16 mm。
- 手术通常在局部麻醉下进行;无导尿管率为85.2%,并发症率为30.83%。
- 主要并发症包括尿路感染(17.2%)、钙化(12.6%)、刺激症状(12.2%)和急性尿潴留(10.4%)。
- 12个月随访期间,支架移除或重置的失败率为14.8%;国际前列腺症状评分总体改善9.85分,最大尿流率和排尿后残余尿量平均改善分别为6.62 ml/sec和147 ml。
局限性
- 总体偏倚风险被评为高或非常高。
- 作者认为需要前瞻性研究来证实这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This review aims to identify and summarize the current literature on the use of prostatic stents or nitinol devices as minimally invasive techniques for the management of lower urinary tract symptoms (LUTS) resulting from benign prostatic hyperplasia (BPH). METHODS: A comprehensive search of the literature was conducted until October 2023. Only original articles written in English were considered for inclusion. This review has been registered in PROSPERO (registration number CRD42023474884). RESULTS: Thirty-eight articles were included (2618 patients). Generally, the risk of bias was deemed as high or very high. The most frequently investigated stents were the UroLume, followed by the Memokath/Memotherm. The mean age was 72.01 ± 5.6 years, with a mean prostate volume of 48.27 ± 12.8 cc and a mean urethral length of 40.53 ± 9.16 mm. Surgeries were usually performed under local anesthesia. The rates of catheter-free status and complications were 85.2% and 30.83%, respectively. The primary complications included urinary tract infections (17.2%), followed by calcifications (12.6%), irritative symptoms (12.2%), and acute urinary retention (10.4%). During a follow-up period of 12 months, the failure rate intended as stent removal or repositioning was 14.8%. The International Prostate Symptom Score (IPSS) showed an overall improvement of 9.85 points. The mean improvement in maximum flow rate and post-void residual volume were 6.62 ml/sec and 147 ml, respectively. CONCLUSIONS: Prostatic stents remain an efficient choice for addressing obstructive symptoms from BPH, offering the advantage of being performed under local anaesthesia, relieving symptoms with good functional outcomes and a low incidence of major complications. Prospective studies are needed to corroborate these results.
引用
- Cerrato C, Antoniou V, Somani BK, et al. Prostatic stents: a systematic review and analysis of functional outcomes and complication rate. Prostate Cancer Prostatic Dis. 2024. PMID: 39516581. doi:10.1038/s41391-024-00915-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。